Press Releases

MGEN $7.63   $ (0.19) (2.55)%

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
11/8/2017
4:05 PM ET
Earnings Release

miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update

11/8/2017

MRG-106 Phase 1 trial expanded to include additional oncology indications, enrollment commencedMRG-201 expected to advance into a Phase 2a trial in cutaneous fibrosis in the first half of 2018MRG-110...

 Continue Reading
11/7/2017
4:05 PM ET
Press Release

miRagen Therapeutics to Participate in Four Investor Conferences in November

11/7/2017

BOULDER, Colo., Nov. 07, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapi...

 Continue Reading
11/1/2017
4:05 PM ET
Press Release

miRagen Therapeutics to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 8, 2017

11/1/2017

BOULDER, Colo., Nov. 01, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) will report its third quarter 2017 financial results on Wednesday, November 8, 2017, after the close of the...

 Continue Reading
11/1/2017
9:00 AM ET
Press Release

miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the 2017 American Society of Hematology Annual Meeting

11/1/2017

BOULDER, Colo., Nov. 01, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
10/18/2017
7:00 AM ET
Press Release

miRagen Therapeutics Announces Five Presentations at the DIA Oligonucleotide-Based Therapeutics Conference

10/18/2017

BOULDER, Colo., Oct. 18, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
Displaying 1 to 5 (of 34 releases)